Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Decnupaz Coverage Update | OpenPa…
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0304

    Decnupaz (pivekimab sunirine-pvzy) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0304 alerts

    Get alerted when Policy CC-0304 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior authorization review for Decnupaz (pivekimab sunirine-pvzy). Coverage may be approved for individuals younger than 19 years or for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN); other indications are not approved.

    Policy Summary
    PayerEmpire Bluecross
    PolicyDecnupaz (pivekim sunirine-pvzy) Coverage Criteria
    Policy CodePolicy CC-0304
    Change TypeModified
    Effective DateJuly 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation showing that the individual is under 19 years of age or has a diagnosis of BPDCN.
    SourceLink
    POLICY UPDATE CHANGES

    HCPCS code C9399 was removed from the policy effective September 30, 2026.

    HCPCS code C9313 was added effective October 1, 2026 for injection of pivekimab sunirine-pvzy.

    2Alternative approval pathways
    <19 yearsAge-based approval criterion
    BPDCNDisease-specific covered indication
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Current HCPCS codes listed
    Black boxHepatotoxicity and hepatic veno-occlusive disease warning

    Coverage Criteria

    Initial approval

    Requests may be approved if either of the following criteria is met:

    Approval criteria

    • Age criterion: Individual is under 19 years of age.under 19 years
    • Disease criterion: Individual has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN).diagnosis of BPDCN

    All other indications are not approved.

    Requests may not be approved when the approval criteria are not met.

    Coding

    HCPCSHCPCSCovered
    C9313Injection, pivekimab sunirine-pvzy, 0.01 mg [Decnupaz]
    J9999Not otherwise classified, antineoplastic drugs [when specified as Decnupaz (pivekimab-sunirine-pvzy)]
    ICD-10 DiagnosisICD-10Covered
    C86.40Blastic NK-cell lymphoma not having achieved remission [blastic plasmacytoid dendritic cell neoplasm (BPDCN)]

    Provider Actions

    Prior Authorization

    Confirm prior authorization eligibility

    Prior authorization or clinical review may be required under the member’s medical benefit. Decnupaz may be approved when the individual is under 19 years of age or has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

    • Approval pathways are alternatives: under 19 years of age or diagnosis of BPDCN.
    Documentation Required

    Document age or BPDCN diagnosis

    Submit documentation supporting either that the individual is under 19 years of age or that the individual has a diagnosis of BPDCN.

    • Document the individual’s age when using the age-based pathway.
    • Document the BPDCN diagnosis when using the disease-specific pathway.

    Background

    Decnupaz (pivekimab sunirine-pvzy) is a CD123-directed antibody-drug conjugate primarily used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive and rare malignancy of the bone marrow and blood that may involve the lymph nodes and skin and may present as or evolve into acute leukemia. Its efficacy was evaluated in the CADENZA trial in treatment-naive and relapsed or refractory BPDCN. Decnupaz carries a black box warning for hepatotoxicity, including hepatic veno-occlusive disease; liver tests and total bilirubin should be monitored before each dose.

    Definitions

    Definitions
    Complete Response (CR)The disappearance of all signs of cancer as a result of treatment; also called complete remission; does not indicate the cancer has been cured.

    Initial Decnupaz Approval

    Initial Decnupaz approval

    Requests for Decnupaz may be approved if either of the following criteria is met:

    Initial approval criteria

    • Age: Individual is under 19 years of age.under 19 years
    • Diagnosis: Individual has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN).BPDCN
    Policy Summary
    PayerEmpire Bluecross
    PolicyDecnupaz (pivekim sunirine-pvzy) Coverage Criteria
    Policy CodePolicy CC-0304
    Change TypeModified
    Effective DateJuly 28, 2026
    Last ReviewJun 8, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation showing that the individual is under 19 years of age or has a diagnosis of BPDCN.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider ActionsBackgroundDefinitionsInitial Decnupaz Approval
    Denial Risk

    Avoid criteria-related denial

    Requests may not be approved when the individual is not under 19 years of age, does not have BPDCN, or the request is for any other indication.

    • The approval criteria must be met.
    • All other indications are not approved.